5-Amino-1MQ
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
A finishing tool for lean users whose fat loss has stalled: 5-amino-1MQ inhibits adipose NNMT, preserving NAD+ precursors in fat cells so lipolysis can keep moving during prolonged caloric restriction.
No serious adverse events reported at standard doses, but no human safety trials exist — the compound's benign profile is based entirely on animal models and anecdotal community experience.
A finishing tool for lean users whose fat loss has stalled: 5-amino-1MQ inhibits adipose NNMT, preserving NAD+ precursors in fat cells so lipolysis can keep moving during prolonged caloric restriction.
Usually mild at standard doses: late-day dosing can disturb sleep, early-cycle headaches can occur, and oral dosing can irritate the stomach when taken empty. The main biochemical watch item is homocysteine if use is prolonged or stacked with other NMT inhibitors. No controlled human safety trials exist.
Useful because it does not suppress appetite, stimulate the CNS, or push thyroid/adrenergic pathways. Its value is narrow: it belongs late in a cut, after diet, training, and more established fat-loss levers are already controlled.
Highly situational. Lean, plateaued users in a sustained deficit report the clearest incremental benefit over 2-4 weeks. Users at higher body-fat levels often report little because adipose NAD+ recycling is not necessarily their limiting bottleneck.
Do not combine high-dose EGCG (green tea extract) with 5-amino-1MQ — both inhibit NMT and the combination risks over-suppression of methylation with potential homocysteine elevation.
Intro
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of NNMT — nicotinamide N-methyltransferase — the enzyme responsible for breaking down nicotinamides in adipose tissue.
Despite being sold and discussed alongside peptides in non-approved compound discussions, it is technically not a peptide. It is an orally bioavailable small molecule that works intracellularly in fat cells, not at cell surface receptors.
The mechanism is highly targeted: 5-amino-1MQ inhibits methylation of nicotinamide specifically within adipose tissue and does not affect the liver, which is the primary site of methylation for most biological compounds. By blocking NNMT in adipose, the compound preserves NAD+ precursors (NMN, NADH, and related cofactors) within fat cells — maintaining the energetic machinery that drives lipolysis. The result is continuous fat release even during prolonged caloric restriction, when NNMT activity normally upregulates and adipose NAD+ cycling slows.
In diet-induced obesity mouse studies, 5-amino-1MQ produced dose-dependent reductions in body weight and fat mass, improved insulin sensitivity and glucose tolerance, suppressed hyperinsulinemia, and attenuated hepatic steatosis — all without reducing food intake. The effects were metabolic, not anorectic. No human clinical trials exist.
The compound's community positioning is explicit: it is not a broad fat burner and not useful at higher body fat percentages. Practitioners consistently frame it as a late-stage tool — deployed at 6-8% body fat or when a prolonged cut has produced metabolic adaptation that standard compounds can no longer overcome. Using it earlier is described as the most common misapplication.
Observed Effects
The dominant reported experience is sustained energy and improved fat loss momentum during a prolonged cut — particularly in users who had plateaued on other compounds.
The energy effect appears within the first few days and is attributed to improved NAD+ availability in adipose tissue (and possibly peripheral tissues) supporting mitochondrial function. The fat loss support is more gradual, typically becoming perceptible over 2–4 weeks.
In animal models, the primary measurable effects were: dose-dependent reduction in body weight and fat mass, improved oral glucose tolerance, normalized insulin sensitivity, reduced liver triglyceride accumulation, and correction of elevated liver enzymes (ALT, AST). These effects occurred without food intake changes — confirming the mechanism is metabolic, not behavioral.
Community users most commonly report improved workout endurance and sustained fat loss continuation that had stalled. Some report a mild libido improvement — this appears anecdotally and is not mechanistically explained, though it may reflect downstream metabolic improvement. Energy improvement is the most consistent first-week report; body composition changes require several weeks of consistent use within a caloric deficit to become visible.
The compound is consistently described as highly user-specific. At the appropriate lean threshold, the effect is measurable and adds a clear incremental edge to a fat loss phase. At higher body fat percentages, the NAD+ recycling bottleneck in adipose is not the limiting factor, and users report little to no effect.
Field Reports
The dominant positive experience in the community is fat loss continuation: users who had plateaued on other compounds — including clenbuterol, injectable carnitine, and GLP-1 agonists — report that 5-amino-1MQ provided the final incremental push that moved the scale again. The effect is rarely dramatic in isolation; it's described as the 'last little edge' by practitioners with personal experience, not a primary fat loss driver.
Energy improvement is the most consistent early-cycle report, typically appearing within the first few days. Users attribute this to improved mitochondrial function via NAD+ restoration in adipose and possibly peripheral tissues. The energy effect is described as clean and metabolic — not stimulant-like, not wired — more analogous to feeling well-rested and metabolically supported than to a pre-workout.
The compound is notably user-specific. Some individuals at appropriate leanness report clear and measurable effects. Others at the same body fat percentage with similar protocols see little. Practitioners interpret this as indicating that NAD+ recycling in adipose is not universally the bottleneck — other factors (thyroid function, insulin sensitivity, cortisol, sleep) can be the actual limiting variable instead.
Negative experiences are typically mild: mild headache in the first 1–3 days, possible insomnia if dosed too late, and stomach discomfort on an empty stomach. Product-quality anxiety is common because identity, purity, and dose accuracy are harder to verify outside regulated products.
Community Consensus
5-amino-1MQ occupies a specific and respected niche in the performance and biohacking community — the 'finishing compound' for lean individuals.
Its reputation was largely built by a small number of practitioner-educators who were early adopters and were explicit about the narrow deployment window: the compound is most effective at 6% body fat or lower, or when dieting for extended periods where metabolic adaptation has slowed fat loss despite all other interventions.
The compound's community reputation benefits from its explicit mechanistic profile: practitioners who explain it clearly — NNMT inhibition in adipose, NAD+ preservation, continuous fat release — give users a concrete model for why it should and shouldn't work. This clear mechanism has improved appropriate use and reduced disappointment from users who deploy it at the wrong time.
In GLP-1 communities, 5-amino-1MQ has gained significant traction as an add-on to semaglutide and tirzepatide protocols. Whether it meaningfully enhances GLP-1 outcomes is debated — skeptics note the impossibility of isolating its effect in multi-compound stacks, and some community members push back on influencer-driven promotion that frames it as universally effective. The honest community consensus is that evidence is preclinical only and that most community reports are confounded.
The longevity angle — NAD+ preservation as an anti-aging mechanism via SIRT-1 activation — has brought the compound into biohacking circles alongside NMN, NR, and resveratrol as part of metabolic healthspan stacks. This use case has weaker practitioner support but aligns with the animal model data showing improved metabolic markers even beyond body composition.
Risks & Monitoring
At standard doses, 5-amino-1MQ has a minimal adverse effect profile. There are no serious adverse events reported in the community at typical use doses, and no human safety data beyond case-level self-reporting exists.
Dose-dependent and manageable effects: Mild insomnia if taken in the evening (the metabolic activation effect can disrupt sleep architecture — morning and early-afternoon dosing is preferred). Mild headaches in the first few days of a cycle, which typically resolve. GI discomfort on an empty stomach — resolved by co-administration with food.
The most clinically relevant risk is NMT over-suppression with chronic use or stacking: nicotinamide N-methyltransferase is involved in the methyl cycle, and chronically inhibiting it can potentially shift SAM/SAH balance and elevate homocysteine. Practitioners who monitor bloodwork flag homocysteine as the key early indicator of excessive NMT suppression. This risk is amplified by stacking multiple NMT inhibitors — EGCG (green tea extract) is also an NMT inhibitor and should not be combined with 5-amino-1MQ at high doses.
Product-quality risk is a practical concern: low-quality, mislabeled, or incorrectly dosed products would create contamination and dose-accuracy risk, as with any non-approved research compound.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
The article identifies homocysteine as the recommended baseline biomarker for extended cycles or NMT-inhibitor stacks. It is the key early indicator of excessive NNMT/NMT suppression because methyl-cycle balance can shift through SAH accumulation and homocysteine elevation. The standard-cycle prose does not make baseline homocysteine a universal safety gate.
The article's 'Monitoring' subsection explicitly recommends metabolic panels (fasting glucose, insulin) as useful to verify the insulin sensitivity benefit if running alongside a fat loss protocol. Baseline anchors the trajectory for the article's documented insulin-sensitization mechanism.
General pre-cycle context rather than a compound-specific safety gate. The article frames 5-amino-1MQ for very lean users in prolonged deficits, where hydration, electrolytes, kidney function, and glucose status can be useful background before adding another metabolic variable.
Standard pre-treatment baseline. The article notes no serious adverse events in the community at typical doses, so this is general due diligence rather than a compound-specific concern.
Interpretive methyl-cycle context rather than a direct 5-amino-1MQ safety gate. Because the article identifies homocysteine elevation as the key over-suppression signal, B12 and folate can help explain an abnormal homocysteine reading during extended use or redundant NMT-inhibitor stacking.
The article specifies a check at 8-12 weeks as covering the main NMT-suppression concern, especially for extended cycles or redundant NMT-inhibitor stacking. This is the primary monitoring touchpoint, but the article also says no routine bloodwork is required for a standard cycle.
Re-check at 8-12 weeks alongside the homocysteine cadence. Verifies the insulin-sensitization benefit the article describes is materializing — useful objective data for users running 5-amino-1MQ as the metabolic adjunct in a fat loss protocol rather than as a standalone.
The article positions 5-amino-1MQ as a finishing compound for users at 6-8% body fat who have plateaued. DEXA at 8-12 weeks objectively confirms whether fat mass continued to drop in the deployment window — useful given the narrow scenario the compound is appropriate for and the cost-per-useful-phase the article flags.
Post-cycle re-check after 4-6 weeks off-compound if homocysteine rose midcycle, the cycle was extended, or another NMT inhibitor was used. Confirms normalization once NNMT inhibition is removed; not needed as a universal post-cycle requirement for short uncomplicated use.
Post-cycle re-check 4-6 weeks off. Establishes the durability of the insulin-sensitization benefit once the pharmacologic stimulus is removed — useful data for deciding whether subsequent cycles are warranted given the article's narrow deployment-window framing.
Avoid With
Do not combine 5-Amino-1MQ with the following. Sorted highest-severity first.
Why:EGCG is also a nicotinamide N-methyltransferase inhibitor. Combining high-dose EGCG with 5-amino-1MQ stacks two NMT inhibitors, risking over-suppression of the methyl cycle with potential homocysteine elevation as a downstream consequence.
What to do:Low-dose EGCG from dietary green tea is unlikely to be problematic. The concern is with high-dose EGCG supplementation (600+ mg EGCG equivalent). Monitor homocysteine if using any combination of NMT inhibitors chronically. Homocysteine is commonly used as a practical biomarker for chronic NMT over-inhibition.
Why:Chronic over-suppression of nicotinamide N-methyltransferase — beyond the adipose-targeted NNMT activity — can affect systemic methyl group availability via the SAM/SAH balance. The methyl cycle connects to homocysteine, B12, folate metabolism, and downstream epigenetic regulation.
What to do:Theoretical concern; not empirically quantified. Practical safeguard: baseline and periodic homocysteine monitoring during any extended 5-amino-1MQ cycle, especially if stacking additional NMT-inhibiting compounds or supplements.
Protocols By Goal
Late-stage fat loss / contest prep: Reported use clusters around 6-8% body fat when fat loss has stalled despite a sustained caloric deficit.
Oral 100-150 mg/day split-dose alongside NMN 150-250 mg or NR 500-1,000 mg. SLU-PP-332 can be added for complementary mitochondrial activation. Reported runs often cover 8-10 weeks of a final cut phase. This is the primary and most evidence-supported use case, but still not validated as a clinical protocol.
Longevity / anti-aging metabolic support: Lower-dose continuous use (50-100 mg/day oral, 1x daily) within a broader mitochondrial support stack: MOTS-c + SS-31 + NAD+ + Methylene Blue + 5-amino-1MQ. The NAD+ preservation mechanism is relevant to the aging-related decline in adipose metabolic function even outside of active fat loss. Elderly metabolic fatigue is a secondary practitioner-identified use case.
GLP-1 complement: Some users on semaglutide or tirzepatide add 5-amino-1MQ to address the metabolic efficiency side of fat burning while the GLP-1 handles appetite. Dose: standard 100-150 mg oral. Note: attributing fat loss effects is confounded in this combination - GLP-1 agonists are potent drivers independently.
Not recommended: Reports generally discourage use at body fat percentages above 10-12%. The NNMT bottleneck is not the limiting factor in fat loss at these percentages, and the compound will produce little to no measurable effect. Avoid off-season use.
Dosing Details
Oral (primary route): Standard starting dose is 50 mg/day for the first 1-2 weeks to assess individual tolerance.
Maintenance dose is 100-150 mg/day, typically split as 50 mg upon waking + 50 mg afternoon + optional third 50 mg dose no later than early afternoon if sleep is not affected. Most practitioners anchor to the 100-150 mg/day range with the split-dose architecture. Once-daily oral dosing (100-150 mg AM) is also used and is easier to maintain consistently.
Cycle length: 8-12 weeks on, 4-8 weeks off for oral protocols. Some practitioners favor shorter cycles with injectable presentations.
Timing: Morning administration is commonly reported. Some users time dosing before physical activity, but this should be read as observed practice rather than validated instruction. Avoid evening dosing if insomnia is a concern.
Injectable presentations: Reported injectable dosing is substantially lower than oral - community reports cluster around 1-2 mg per dose (vs. 100-150 mg oral), reflecting the bioavailability difference when bypassing first-pass hepatic metabolism. Preparation details are not standardized and should not be treated as reader-specific injection guidance.
Food: Oral form can be taken with or without food. If GI discomfort occurs, co-administer with a meal.
NMN/NR pairing is standard: 150-250 mg NMN with meals, or 500-1,000 mg NR daily. The combination creates a push-pull NAD+ effect: 5-amino-1MQ inhibits NAD+ precursor breakdown in adipose while NMN/NR provides additional substrate for synthesis.
Stacks & Alternatives
The canonical companion to 5-amino-1MQ. The two compounds work on opposite ends of the NAD+ equation in adipose: 5-amino-1MQ inhibits breakdown of NAD+ precursors while NMN/NR supplies additional substrate for NAD+ synthesis. Combined, they produce more robust NAD+ elevation in adipose than either compound alone. Practitioner-endorsed as the foundational 5-amino-1MQ stack.
Synergistic fat metabolism stack. SLU-PP-332 activates ERR nuclear receptors driving mitochondrial biogenesis and fatty acid oxidation; 5-amino-1MQ enhances the NAD+ environment that SLU-PP-332 activation requires. The mechanisms are complementary: SLU-PP-332 creates the demand for energy metabolism, 5-amino-1MQ sustains the NAD+ supply that supports it.
Mitochondrial support + anti-aging angle. Methylene Blue supports the electron transport chain directly and is described as the most cost-effective single mitochondrial support compound. Combines with 5-amino-1MQ in longevity stacks targeting mitochondrial function and metabolic efficiency. Non-overlapping mechanisms.
Full mitochondrial support tier per practitioner-recommended neuroprotection/longevity stacks. MOTS-c drives mitochondrial biogenesis and metabolic flexibility; SS-31 protects cardiolipin and reduces mitochondrial oxidative stress. 5-amino-1MQ handles the adipose NAD+ environment. Together they form a comprehensive mitochondrial support protocol.
Growing community practice: GLP-1 handles appetite suppression and systemic metabolic improvement while 5-amino-1MQ targets the cellular fat metabolism side. Whether 5-amino-1MQ adds meaningful incremental effect on top of GLP-1 agonists is contested — GLP-1 agonists are powerful enough that isolating 5-amino-1MQ's contribution is difficult. Best justified when fat loss has slowed despite active GLP-1 use.
Alternatives
Stack Cost
Specialist tax: biologically light for hormones and organs, but narrow in use case, human evidence, product-quality uncertainty, and methyl-cycle monitoring.
The recommendedPanels section makes homocysteine the main monitor for extended cycles or NMT-inhibitor stacks because the article links chronic NNMT/NMT over-suppression to SAM/SAH balance and possible homocysteine elevation. Fasting glucose and insulin are also recommended to verify metabolic effect rather than assuming fat-loss benefit.
The stackingConflicts section flags high-dose EGCG and other NMT inhibitors as caution-level conflicts. The tax is not broad drug complexity; it is avoiding redundant NMT inhibition and checking homocysteine if another methylation-active agent is used.
The practicalConsiderations and practicalitiesSummary sections describe a narrow deployment window at very low body fat and note product-identity and purity uncertainty. That makes the effective cost and product-quality burden higher than the headline price.
AdverseEffects describes mild insomnia when dosed late and headaches early in a cycle, with morning or early-afternoon dosing as the practical mitigation. This is a timing discipline issue, not a primary CNS risk.
The article is non-hormonal and has no HPG-axis suppression signal, but the reviewed evidence shows no human pregnancy, lactation, or female-specific clinical safety data. Pregnancy and lactation therefore raise the tax by uncertainty, not by known androgenic mechanism.
- ·Treat 5-amino-1MQ as a finishing-tool slot, not a foundational fat-loss driver; the evidence indicates it is most appropriate after diet, training, and broader fat-loss tools are already optimized.
- ·Do not stack casually with high-dose EGCG or other NMT inhibitors; if that lane is already occupied, homocysteine monitoring becomes mandatory.
- ·It does not consume an androgen, GH/IGF, GLP-1, or stimulant lane, so it can sit under those protocols only when the user plateau and leanness make the adipose NAD+ bottleneck plausible.
- ·If the user is not already lean or is using a powerful GLP-1 where the incremental contribution cannot be isolated, the article's own framing makes the stack-tax-to-benefit ratio unfavorable.
- ·Baseline and midcycle homocysteine for extended cycles or any NMT-inhibitor stack.
- ·Baseline and midcycle fasting glucose plus fasting insulin if the user wants objective confirmation of the insulin-sensitivity claim.
- ·Morning or early-afternoon dosing discipline to reduce insomnia risk.
- ·Cycle breaks after the article's 8-12 week on-period, with 4-8 weeks off before repeating.
- ·Product identity and batch-confidence discipline because the article flags mislabeling and dose-accuracy uncertainty.
The article does not describe a severe acute safety burden, but it repeatedly frames correct use as situational: low body fat, prolonged caloric deficit, plateau identification, methyl-cycle monitoring, and product-quality caution. That is beyond a casual beginner fat-loss add-on.
- ·Above the article's lean deployment window or using it as a first fat-loss compound.
- ·Unable to get baseline labs or unwilling to stop if homocysteine rises.
- ·Pregnant, lactating, trying to conceive, or relying on absence of human data as proof of safety.
- ·Already stacking multiple experimental metabolic compounds without clear attribution.
The article describes no suppression, withdrawal, or rebound mechanism; stopping primarily removes the adipose NNMT-inhibition effect and should reduce the methyl-cycle concern.
- ·Loss of the late-cut fat-loss edge
- ·Return of plateau if the underlying diet or metabolic bottleneck remains
- ·Need to re-check homocysteine if it was elevated midcycle
Use only after the article's stated prerequisites are met: already lean, prolonged deficit, adherence controlled, and other limiting variables such as thyroid, insulin sensitivity, cortisol, and sleep considered.
Follow the article's homocysteine monitoring recommendation, avoid high-dose EGCG/NMT-inhibitor stacks, and stop or deload if homocysteine rises.
Move dosing to morning or early afternoon, take oral doses with food if GI discomfort occurs, and discontinue if symptoms persist.
Do not treat uncertain identity, purity, or dose labeling as a minor issue; product-quality ambiguity can invalidate both dosing assumptions and safety expectations.
The reviewed evidence provides no human pregnancy, lactation, or fertility safety data for NNMT inhibition.
The article's main biochemical concern is SAM/SAH disruption with homocysteine as the practical readout.
The stackingConflicts section identifies redundant NMT inhibition as the clearest stack conflict.
The article says higher-body-fat users often report little to no effect because adipose NAD+ recycling is not necessarily the limiting factor.
Practical Setup
Who it's for: Users at 6-8% body fat or lower who are in a prolonged deficit and have hit a fat loss plateau despite consistent diet, training, and other fat loss compounds.
Also relevant for older individuals experiencing metabolic fatigue - the NAD+ recycling decline is more pronounced with age, making the compound more impactful in this population. Not appropriate for general fat loss or users above 10-12% body fat.
Product quality: identity, purity, dose accuracy, and route consistency are the practical constraints. Oral and injectable presentations create different dose-translation and quality risks, and misidentified products would materially change the safety profile.
Monitoring: Homocysteine is the recommended baseline biomarker if running extended cycles or stacking NMT-inhibiting compounds. A baseline before starting and a check at 8-12 weeks covers the major concern. No routine bloodwork is required for a standard cycle, but metabolic panels (fasting glucose, insulin) are useful to verify the insulin sensitivity benefit if running alongside a fat loss protocol.
Cost context: headline pricing can look modest, but the narrow deployment window makes the effective cost-per-useful-phase higher than it appears. Treat it as a specialty finishing compound, not a daily supplement.
Physical activity synergy: timing before training is a common observed pattern, especially for morning fasted cardio, but it should not be treated as validated instruction.
Mechanism Deep Dive
5-amino-1MQ inhibits NNMT — nicotinamide N-methyltransferase — specifically within adipose tissue.
NNMT catalyzes the N-methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide and S-adenosylhomocysteine (SAH). In adipose tissue, particularly in obese or chronically calorie-restricted states, NNMT activity is elevated — it consumes nicotinamide at an accelerated rate, limiting the substrate available for NAD+ synthesis via the salvage pathway.
By blocking NNMT, 5-amino-1MQ preserves nicotinamide in adipose cells, increasing intracellular pools of NMN, NAD+, NADH, and NADP+. Elevated NAD+ in adipose tissue has two downstream consequences: (1) it fuels the oxidative metabolism required for lipolysis and fatty acid mobilization, and (2) it activates SIRT-1 — a NAD+-dependent deacetylase associated with mitochondrial biogenesis, fat oxidation, and metabolic health markers linked to longevity.
Critically, the mechanism is adipose-specific at the doses studied. The liver — the primary site of methylation for most endogenous and exogenous compounds — is not meaningfully affected. This selectivity is what produces the targeted adipose fat metabolism effect without broad disruption of systemic methylation.
The half-life is estimated at 4–6 hours based on structural pharmacokinetics, supporting split-dose administration to maintain sustained NNMT inhibition throughout the day. Oral bioavailability has been demonstrated in rat pharmacokinetic studies using LC-MS/MS methods. Injectable bioavailability bypasses hepatic first-pass metabolism, which explains why the effective injectable dose is substantially lower than the oral dose.
The connection to the methyl cycle (via SAM consumption by NNMT) is the basis for the homocysteine monitoring recommendation: if NNMT is over-suppressed — especially when stacked with other NMT inhibitors — the methyl cycle balance can shift, with SAH accumulation and downstream homocysteine elevation as a potential consequence.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
In diet-induced obesity mouse studies, 5-amino-1MQ produced dose-dependent reductions in body weight and fat mass, improved insulin sensitivity and glucose tolerance, suppressed hyperinsulinemia, and attenuated hepatic steatosis without reducing food intake.
This is preclinical obesity-model evidence and should not be generalized as proven human fat-loss efficacy.
No human clinical trials exist.
The human profile in this article is extrapolated from animal/PK work and community reports, not controlled efficacy or safety trials.
Practitioners frame 5-amino-1MQ as a late-stage tool deployed at 6-8% body fat or when a prolonged cut has produced metabolic adaptation.
This is deployment guidance from community/practitioner framing, not a validated clinical responder threshold.
Fat loss support is more gradual, typically becoming perceptible over 2-4 weeks.
Timing is anecdotal and should be read as community expectation setting, not a measured clinical onset.
At the appropriate lean threshold, the effect is measurable and adds a clear incremental edge; at higher body fat percentages, users report little to no effect.
The responder pattern is article-grounded but uncontrolled and confounded by diet, GLP-1 use, training, sleep, and concurrent compounds.
Standard starting oral dose is 50 mg/day for the first 1-2 weeks to assess tolerance.
This is community dosing convention, not a clinical dose-ranging study.
Maintenance dose is 100-150 mg/day, often split as 50 mg morning, 50 mg afternoon, and optional 50 mg before bed.
Human dose is based on community practice; the available discussion also contains disagreement that no true human protocol exists.
Cycle length is 8-12 weeks on and 4-8 weeks off for oral protocols.
Cycle timing is practical risk management around sparse human safety data, not an evidence-proven optimal schedule.
Community injectable reports cluster around 1-2 mg per dose versus 100-150 mg oral.
Injectable human dosing is especially uncertain and should not be treated as a standardized protocol.
Injectable 5-amino-1MQ reports use much lower nominal doses than oral reports, but preparation details are not standardized.
This preserves dose-variation signal without giving injection-preparation instructions.
NMN/NR pairing is standard: 150-250 mg NMN with meals, or 500-1,000 mg NR daily.
This scopes the support-stack dosing convention; it is not direct evidence that the combination improves human outcomes.
Not appropriate for general fat loss or users above 10-12% body fat.
This is a practical selection rule from the article community framing, not a clinically validated body-fat cutoff.
Homocysteine baseline before starting and a check at 8-12 weeks covers the major concern.
Monitoring cadence is grounded in the article methyl-cycle risk model rather than a clinical safety trial.
Pricing varies by route, claimed purity, and batch-testing support.
Pricing is market-context evidence and can drift quickly by route, purity testing, and product channel.
Rat PK work found average oral bioavailability of 38.4% and terminal half-life values of about 3.8 hours IV and 6.9 hours oral.
This supports oral absorption and PK plausibility, but it does not establish human half-life or human dose equivalence.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.